+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin



A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin



Alimentary Pharmacology and Therapeutics 24(7): 1079-1086



There is yet no established treatment for chronic hepatitis C patients non-responder to standard interferon and ribavirin. To evaluate efficacy and safety of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in such patients. 161 non-responders to standard interferon and ribavirin were randomized into two groups: 81 patients (Group 1) were given weekly Peg-IFN-alpha2a 180 microg plus ribavirin 1,000-1,200 mg/daily for 12 months, 80 patients (Group 2) received weekly Peg-IFN-alpha2a 180 microg plus ribavirin 1,000-1,200 mg/daily and amantadine 200 mg/daily for 12 months. At the end of follow-up, HCV-RNA was negative in 29.6% of Group 1 and in 21.2% of Group 2 patients (P = 0.22). Patients with genotypes 1 and 4 responded better to bi-therapy (21.7%) than to triple therapy (17.3%, P = 0.5) while among patients with genotypes 2 and 3 there was a trend towards a higher sustained virological response rate when retreated with triple treatment (80% vs. 75%, P = 0.82). On multivariate analysis, genotype 1 or 4, high body mass index and >20% reduction of Peg-interferon were associated with the treatment failure. The addition of amantadine does not improve the overall SVR rate in non-responder patients retreated with Peg-IFN and ribavirin; however, about 30% of non-responders may achieve a sustained response, in particular patients with genotypes 2 and 3 show a high SVR (75%).

(PDF emailed within 0-6 h: $19.90)

Accession: 048107997

Download citation: RISBibTeXText

PMID: 16984502

DOI: 10.1111/j.1365-2036.2006.03098.x


Related references

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C. Journal of Viral Hepatitis 12(3): 292-299, 2005

Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients. Intervirology 53(3): 146-153, 2010

Controlled trial with pegylated interferon-alpha2b plus ribavirin retreatment in patients with chronic hepatitis C not responding to a previous antiviral treatment with standard interferons combined with ribavirin. Journal of Hepatology 38(Suppl. 2): 176, 2003

Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy). Journal of Medical Virology 82(12): 2027-2031, 2011

Treatment with amantadine + ribavirin + interferon in patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy. Gastroenterology 118(4 Suppl 2 Part 2): AASLD A143, 2000

Retreatment with pegylated interferon alpha2b plus ribavirin in patients with chronic hepatitis c not responding to a previous antiviral treatment with standard interferons combined with ribavirin. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No T1216, 2003

Treatment with pegylated-interferon alpha-2b +ribavirin in relapsers to standard interferon+ribavirin in chronic hepatitis C Efficacy and safety results from a randomized multicentric French study. Hepatology 36(4 Part 2): 359A, 2002

A randomized trial of pegylated interferon alpha-2B and ribavirin vs pegylated interferon alone in patients with chronic hepatitis C who have failed standard therapy Interim results after 24 weeks. Gastroenterology 123(1 Suppl.): 77, 2002

Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients. Alimentary Pharmacology and Therapeutics 30(4): 352-363, 2010

A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C. Journal of Gastroenterology 42(5): 362-367, 2007

ANRS HC02-RIBAVIC A randomized controlled trial of pegylated-interferon alfa-2b plus ribavirin vs interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 269, 2002

Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine. Wiener Klinische Wochenschrift 116(15-16): 530-535, 2004

Preliminary results of a randomized multicenter controlled trial comparing interferon thrice weekly in combination with ribavirin with interferon daily in combination with ribavirin and amantadine in the treatment of chronic hepatitis C in human immune deficiency virus co-infected patients. Hepatology 36(4 Part 2): 586A, 2002

Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial. Annals of Hepatology 11(1): 52-61, 2012

A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy. Alimentary Pharmacology & Therapeutics 19(3): 339-347, 2004